Dados do Trabalho

Título

1 year events of Firehawk™biodegradable Polymer sirolimus stent guided by intracoronary ultrasound

Resumo

Background: The lifetime presence of durable polymers, even among new-generation drug-eluting stents, has been associated with chronic inflammation, implying late adverse clinical events. Our aim was to assess the performance and mid-term clinical outcomes of the Firehawk™ device in real-world patients, according to daily practices.
Methods: 100 patients, with severe lesions, treated with percutaneous coronary intervention with Firehawk™ stent implantation guided by intravascular imaging, between May 2019 and December 2021.
Results: Mean age was 65.74 ± 6.68 years, 71% male, 53% had diabetes, and 67% multivessel disease. Lesions were B2/C type (61%), mean Syntax score was 18.5 ± 9.34 and LAD was the most frequent treated vessel (41%). Lesions in bifurcation were observed in 35%. A total of 156 lesions were treated with 164 Firehawk™ DES (1.6 stent/lesion). Further DES optimization following intravascular imaging was required in 16% of patients. Procedure success was 100%. All patients completed 1-year follow-up. The 1-year PoCE rate (primary endpoints) was 6%, being DoCE rate (secondary endpoints) 1.0%, with no cases of stent thrombosis (0%).
Conclusion: Based on this study, which was carried out in a Brazilian unique center, the Firehawk™ stent was effective and safe at 12-months follow-up. These findings, and the data available in literature provide additional evidence about the use of the fully biodegradable sirolimus-containing polymer coating Firehawk™ stents in the Brazilian daily clinical practice.

Palavras Chave

Percutaneous Coronary Intervention; DES; Coronary Artery Disease